Gabriele Coppola

Dr. Gabriele Coppola

National Research Council, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
ENEttore Napolitano
Ettore Napolitano
ACAndrea Criscuolo
Andrea Criscuolo
CRClaudia Riccardi
Claudia Riccardi
CECarla L. Esposito
Carla L. Esposito
SCSilvia Catuogno
Silvia Catuogno
Domenica MusumeciDomenica Musumeci
Domenica Musumeci

11 June 2025 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
GCGabriele Coppola
Gabriele Coppola
FCFabiola Cennamo
Fabiola Cennamo
GCGiuseppe Ciccone
Giuseppe Ciccone
MIMaria Luigia Ibba
Maria Luigia Ibba
ARAnnalisa Di Ruscio
Annalisa Di Ruscio
SCSilvia Catuogno
Silvia Catuogno
The possibility of correcting genetic and epigenetic alterations through gene therapies has been considered a cornerstone in oncology. However, modest results have been achieved in clinics, mainly due to inefficient tumor targeting and side effects. Nucleic acid aptamers are three-dimensional folded single-stranded DNAs or RNAs that selectively bind receptors on cellular membranes, being subsequently internalized via receptor-mediated endocytosis. Thanks to this capability, internalizing aptamers have been investigated as targeting moieties to deliver gene therapies more efficiently and selectively in tumor cells. Promising preclinical results suggested that aptamers could represent the long-awaited step forward in cancer gene therapy. Nevertheless, no clinical trials of aptamer-based gene therapies have been carried out two decades after the first preclinical application, indicating the field could not be sufficiently mature for translatability. The review aims to update thestate of the art regarding aptamers' contribution to gene therapy delivery and to critically highlight the main shortcomings that could have hindered clinical evaluations. In addition, pioneering insights regarding the use of aptamers as co-factors in CRISPR/Cas9 technology or as direct epigenetic regulators are also summarized, revealing more extended applicability not limited to the delivery of cancer gene therapies.

Verified
Journal Article
Open access
PDF file
GCGiuseppe Ciccone
Giuseppe Ciccone
MIMaria Luigia Ibba
Maria Luigia Ibba
GCGabriele Coppola
Gabriele Coppola
Silvia CatuognoSilvia Catuogno
Silvia Catuogno
CECarla Lucia Esposito
Carla Lucia Esposito
Non-small-cell lung cancer (NSCLC) is the second most diagnosed type of malignancy and the first cause of cancer death worldwide. Despite recent advances, the treatment of choice for NSCLC patients remains to be chemotherapy, often showing very limited effectiveness with the frequent occurrence of drug-resistant phenotype and the lack of selectivity for tumor cells. Therefore, new effective and targeted therapeutics are needed. In this context, short RNA-based therapeutics, including Antisense Oligonucleotides (ASOs), microRNAs (miRNAs), short interfering (siRNA) and aptamers, represent a promising class of molecules. ASOs, miRNAs and siRNAs act by targeting and inhibiting specific mRNAs, thus showing an improved specificity compared to traditional anti-cancer drugs. Nucleic acid aptamers target and inhibit specific cancer-associated proteins, such as “nucleic acid antibodies”. Aptamers are also able of receptor-mediated cell internalization, and therefore, they can be used as carriers of secondary agents giving the possibility of producing very highly specific and effective therapeutics. This review provides an overview of the proposed applications of small RNAs for NSCLC treatment, highlighting their advantageous features and recent advancements in the field.

10 March 2023 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
MIMaria L. Ibba
Maria L. Ibba
GCGiuseppe Ciccone
Giuseppe Ciccone
Deborah RotoliDeborah Rotoli
Deborah Rotoli
GCGabriele Coppola
Gabriele Coppola
AFAlfonso Fiorelli
Alfonso Fiorelli
CECarla L. Esposito
Carla L. Esposito
The identification of new effective therapeutic options for non-small-cell lung cancer (NSCLC) represents a crucial challenge in oncology. Recent studies indicate that cancer-associated fibroblasts (CAFs) participate in tumor progression by establishing a favorable microenvironment that promotes cancer progression. Therefore, the development of strategies inhibiting the interplay between CAFs and cancer cells is considered a winning approach for the development of effective anti-cancer drugs. Among other factors, the signal transducer and activator of transcription-3 (STAT3) has been reported as a key mediator of CAF oncogenic actions, representing a promising therapeutic target. Here, we applied an aptamer-based conjugate (named Gint4.T-STAT3), containing a STAT3 siRNA linked to an aptamer binding and inhibiting the platelet-derived growth factor receptor (PDGFR)β, to obtain STAT3-specific silencing and interfere with CAF pro-tumorigenic functions. We demonstrated that this molecule effectively delivers the STAT3 siRNA in NSCLC cells, and blocks CAF-induced cancer cell growth and migration and reduced spheroid dimension. In addition, we found that Gint4.T-STAT3 alters CAF phenotype, thus functioning as a double-acting molecule able to inhibit the entire tumor bulk. Our data provide a proof of principle for the targeting of CAF pro-tumor functions through an aptamer-based drug, and can open innovative horizons in NSCLC therapy.

7 January 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
IIIlaria Iacobucci
Ilaria Iacobucci
ICIrene Cipollone
Irene Cipollone
FCFlora Cozzolino
Flora Cozzolino
DIDaniela Iaconis
Daniela Iaconis
CTCarmine Talarico
Carmine Talarico
Maria MontiMaria Monti
Maria Monti
SARS-CoV-2 encodes a 3C-like protease (3CLpro) that is essential for viral replication. This cysteine protease cleaves viral polyproteins to release functional nonstructural proteins, making it a prime target for antiviral drug development. We investigated the inhibitory effects of halicin, a known c-Jun N-terminal kinase inhibitor, on 3CLpro. Mass spectrometry and crystallographic analysis revealed that halicin covalently binds to several cysteine residues in 3CLpro. As expected, Cys145, the catalytic residue, was found to be the most targeted residue by halicin. Secondly, Cys44 was found to be modified, suggesting a potential inhibitory role of this residue. A mutant protease (Cys44Ala) was generated to further understand the function of Cys44. In silico and enzymatic assays showed that the mutation significantly reduced the stability and activity of 3CLpro, indicating the importance of Cys44 in maintaining the active conformation of the protease. Differential scanning fluorimetry assays confirmed this evidence, showing a reduced thermal stability of the mutant compared to the wild-type protease. Our results highlight the potential of halicin as a multi-target inhibitor of 3CLpro and underline the importance of Cys44 in the function of the protease. These findings contribute to the development of effective antiviral therapies against COVID-19 by targeting critical residues in 3CLpro.

24 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
GCGabriele Coppola
Gabriele Coppola
FCFabiola Cennamo
Fabiola Cennamo
GCGiuseppe Ciccone
Giuseppe Ciccone
MIMaria Luigia Ibba
Maria Luigia Ibba
AVAldo Di Vito
Aldo Di Vito
Silvia CatuognoSilvia Catuogno
Silvia Catuogno
Gene therapy is a medical approach capable of correcting genetic and epigenetic alterations in pathological conditions, including cancer. Different strategies have been pursued for cancer gene therapy, aiming to restore the function of tumor suppressor genes or inhibit oncogenes. These comprise the use of CRISPR/Cas9 gene editing technology and therapeutic oligonucleotides, such as microRNAs, anti-microRNAs, small interfering RNAs, DNAzymes, and epigenetic modifiers. However, despite great potential, their broad clinical use is hindered due to the lack of safe and efficient systems for targeted delivery to cancer cells. To this purpose, aptamers could represent an ideal tool. They are short single-stranded oligonucleotides that bind receptors selectively present or overexpressed on cancer cell membranes, often undergoing cell-specific internalization. Thanks to this last feature, numerous internalizing aptamers have been investigated as targeting moiety to deliver therapeutic oligonucleotides, viral vectors, and nanoparticle-based systems in preclinical studies. Here, we summarize the state-of-the-art of aptamer applications in cancer gene therapy, providing key examples and discussing their advantages, limitations, and clinical perspectives.